Sagility Ltd. Share Price

Sagility Ltd Q2 results board meeting on October 27

Sagility’s board will meet on October 27, 2026 to approve unaudited standalone and consolidated Q2 and H1 FY27 results; its insider trading window has been closed since October 1 and will reopen 48 hours after results are announced. In management news, Brian Clayton was appointed Global General Counsel and Senior Management Personnel from October 2, 2026, succeeding Daniel B. Bailey, who resigned for personal reasons. On the brokerage side, Nuvama initiated coverage with a Buy rating and ₹57 target price on October 8, citing Sagility’s payer-focused US healthcare exposure, free cash flow generation, and expected debt repayment that could make it net cash by FY27 end; the firm projects 13% USD revenue CAGR and 19% adjusted EPS CAGR from FY26 to FY29E. Shares closed at ₹44.00 on October 9, with a market capitalisation of about ₹20,574 crore.

See More

Sagility Limited Tests Rising Trendline Support

has slipped 2.09% to close at 42.54, bringing price right down to the rising trendline that has connected its higher lows since the March 2026 base near 36 — a trendline that has already been tested and held twice before, near 38.50 in June and near 42 in September. The stock is now testing this support for a third time, after pulling back from a recent high near 47 within the broader ascending channel. RSI has eased to 36.72, its lowest reading since the channel began, reflecting the loss of momentum behind this pullback. Whether the trendline holds a third time or gives way is the key question, since a break here would put the broader channel structure itself in question. Resistance: 44 (near-term), then 46-48 (upper channel boundary). Support: 42 (current trendline test), then 38.50-39 (prior trendline touch), with 36 as the deeper reference from the base of the channel. A hold at this zone would keep the ascending structure intact and in line with its prior behavior at each trendline test; a sustained close below it would raise the case for a deeper correction toward the lower levels. A trendline that has already been tested and held more than once carries more weight, but no support holds forever — each test still needs to be watched on its own. Disclaimer: This is for educational purposes only and is not investment advice. Please consult your financial advisor before making any investment decisions. SEBI Registered Research Analyst — INH000025212.

See More

Sagility's fundamental growth story remains strong.

Sagility's fundamental growth story remains strong. It is a healthcare-focused BPM/technology-services company serving mainly US payers, providers and PBMs, and Q1 FY27 showed strong revenue and profit growth. The main concern is that margins have softened sequentially, while the stock valuation needs to keep pace with earnings growth. 🟢 Q1 FY27 performance Revenue: ₹1,963.5 crore, +27.6% YoY Adjusted EBITDA: ₹471.6 crore, +27.9% Adjusted EBITDA margin: 24.0% Adjusted PAT: ₹269.7 crore, +35.1% Constant-currency revenue growth was 15.2%. The reported revenue declined about 3% QoQ, but management/analysis indicates that seasonality in certain contracts was a major factor; on a constant-currency organic basis, the underlying sequential growth was healthier. 🚀 Key positive triggers 1. Healthcare BPM remains a structural growth market Sagility focuses on healthcare operations transformation for US payers, providers and PBMs, giving it exposure to a large and relatively specialised outsourcing market. The company has 47,000+ employees globally. 2. CareSeed acquisition The acquisition of CareSeed added 26 clients and strengthens Sagility's capabilities in HEDIS and risk adjustment, areas closely connected with Medicare Advantage. This can improve its ability to win higher-value healthcare contracts. 3. Strong client/deal momentum Q1 included $35.3 million of ACV, indicating continued demand for its services. However, investors should distinguish between organic client additions and those coming through acquisitions. 4. AI and automation opportunity Sagility is increasingly using analytics, automation and GenAI to improve healthcare operations. This can help increase productivity and potentially improve margins over the longer term.

See More

Why technical retracements are important

Why technical retracements are important SEBI RA – Shubh Consultancy – Sunil Kotak – INH000015826 Sagility chart weekly chart trendline drawn on charts we saw technical retracement on charts this is long term chart we have seen bounce back from levels on 36-39 this is crucial support zone on long term charts technical retracement levels are respected very gracefully generally. Other crucial information; Overall It sector is buy now for value investor. Be selective in IT sector Stay with mid to large cap stocks avoid small cap for now Large cap stocks are in acquisition mode for now. This is very good for the sector overall. All this is for information. This is not a buy/sell recommendation. Thank you, Technofunda24

See More

Sagility’s Outsourcing Tailwind

Sagility is gaining from a clear structural shift: more U.S. hospitals are outsourcing work to India, and that can support steady revenue growth for the company. For shareholders, this is generally positive because the business is tied to a large, recurring demand trend rather than a one-off event. Sagility’s latest reported numbers show strong momentum. Revenue for FY25 was about ₹1,971 crore, up 16.58% year on year, while net profit rose to ₹355 crore, up 273.38%. In the June 2025 quarter, revenue was ₹479.61 crore and net profit was ₹96.73 crore, with net margin at 20.47%. Another recent quarter showed revenue of ₹14,166 million, adjusted EBITDA of ₹3,690 million, EBITDA margin of 26.1%, adjusted PAT of ₹2,015 million, and adjusted EPS of ₹0.43. For shareholders, the benefit is straightforward: if U.S. healthcare clients keep shifting work to lower-cost Indian vendors, Sagility can expand volume, improve margins, and increase earnings. That usually helps valuation if execution stays strong. But there are also risks. The company is heavily exposed to U.S. healthcare outsourcing, so any slowdown in client spending, contract losses, pricing pressure, or regulatory changes could hurt growth. The stock can also become expensive if the market prices in too much future optimism too early. Overall, the trend looks beneficial for Sagility shareholders because it gives the company a long runway for growth and margin expansion. Still, the stock remains dependent on execution, client concentration, and sustained outsourcing demand.

See More

Q1FY27 Quarterly Result Announced for Sagility Ltd.

Q1FY27 Quarterly Result Announced for Sagility Ltd.

SEBI RA - Sunil Kotak - Shubh Consultancy - INH000015826 Commercial Services company Sagility announced Q1FY27 results Consolidated Financial Highlights: Total Income: For Q1FY27, total income reached Rs 19,778.06 million, a YoY growth of 27.70% from Rs 15,488.36 million in Q1FY26. On a QoQ basis, it decreased by 3.48% from Rs 20,490.36 million in Q4FY26. Revenue from Operations: Consolidated revenue for Q1FY27 stood at Rs 19,634.83 million, up 27.59% YoY from Rs 15,389.42 million in Q1FY26. It showed a QoQ decrease of 3.00% from Rs 20,242.57 million in Q4FY26. Profit Before Tax (PBT): For Q1FY27, PBT was Rs 2,874.78 million, representing a YoY increase of 36.64% from Rs 2,103.87 million in Q1FY26. Compared to Q4FY26, which was Rs 3,631.84 million, PBT decreased by 20.84% QoQ. Net Profit for the Period: The company reported a net profit of Rs 2,168.11 million in Q1FY27, reflecting a YoY growth of 45.94% from Rs 1,485.59 million in Q1FY26. On a QoQ basis, it decreased by 15.87% from Rs 2,577.27 million in Q4FY26. Earnings Per Share (EPS): Basic EPS for Q1FY27 stood at Rs 0.46, compared to Rs 0.32 in Q1FY26 and Rs 0.56 in Q4FY26. Total Comprehensive Income: Total comprehensive income for Q1FY27 was Rs 2,614.10 million, compared to Rs 1,483.50 million in Q1FY26 and Rs 4,652.87 million in Q4FY26. All this is for information This is not a buy/sell recommendation. Thank you, Technofunda24

See More